Advertisement

Topics

Complement-activating Anti-human Leucocyte Antigen Donor Specific Antibodies in Solid Organ Transplantation

2018-02-22 19:05:22 | BioPortfolio

Published on BioPortfolio: 2018-02-22T19:05:22-0500

Clinical Trials [2918 Associated Clinical Trials listed on BioPortfolio]

Tolerance by Engaging Antigen During Cellular Homeostasis

Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ. Long-term use of these medicines place...

A Retrospective Review - Anti-HLA Antibodies

Transplant rejection following organ transplant occurs because the recipient's immune system attacks the transplanted organ. The recipients immune system recognizes the transplanted organ ...

Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents

This study is being done with the purpose of trying to understand if and why transplant recipients may develop tolerance to their transplanted organ. Tolerance means being able to lower or...

A Cohort Study of Operationally Tolerant Allograft Recipients

Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ. Some organ transplant re...

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

The purpose of this study is to examine the effects of withdrawing steroids on graft rejection and kidney functions in kidney transplant recipients. Graft survival has improved in recent ...

PubMed Articles [10237 Associated PubMed Articles listed on BioPortfolio]

Heparan sulfate is a plasma biomarker of acute cellular allograft rejection.

Despite advances in management of immunosuppression, graft rejection remains a significant clinical problem in solid organ transplantation. Non-invasive biomarkers of graft rejection can facilitate ea...

Novel urinary exosomal biomarkers of acute T cell-mediated rejection in kidney transplant recipients: A cross-sectional study.

Acute rejection is hazardous to graft survival in kidney transplant recipients (KTRs). We aimed to identify novel biomarkers for early diagnosis of acute T cell-mediated rejection (TCMR) in urinary ex...

Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients.

Medication adherence in renal transplant recipients: A latent variable model of psychosocial and neurocognitive predictors.

Estimates indicate that 20-70% of renal transplant recipients are medication non-adherent, significantly increasing the risk of organ rejection. Medication adherence is negatively impacted by lower ev...

Racial Disparity in Kidney Transplant Survival Relates to Late Rejection and is Independent of Steroid Withdrawal.

Black kidney transplant recipients have more acute rejection (AR) and inferior graft survival. We sought to determine whether early steroid withdrawal (ESW) had an impact on AR and death-censored graf...

Medical and Biotech [MESH] Definitions

The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.

An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.

A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.

The immune responses of a host to a graft. A specific response is GRAFT REJECTION.

Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)

More From BioPortfolio on "Complement-activating Anti-human Leucocyte Antigen Donor Specific Antibodies in Solid Organ Transplantation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial